CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

lopinavir/ritonavirWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug2611 Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures Wiki 1.00
drug1374 Losartan Wiki 0.35
drug1103 Hydroxychloroquine Sulfate Wiki 0.28
drug1860 Placebos Wiki 0.24

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D003428 Cross Infection NIH 0.58
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)

Although a number of therapeutics are being utilized by clinicians to treat patients with COVID-19, none have been systematically evaluated in clinical trials. Lopinavir/ritonavir, an antiretroviral medication, showed equivocal but possibly positive efficacy and safety in a RCT conducted in China and published in NEJM in March of 2020. Hydroxychloroquine, an antimalarial and anti-inflammatory medication, has shown potent antiviral activity in vitro and elimination of viral shedding in a small pilot clinical trial. Losartan, an angiotensin II receptor blocker (ARB), has theoretical benefit as SARSCoV-2 appears to bind to lung tissue via Angiotensin-Converting Enzyme 2 (ACE-2) receptors which might be inhibited by ARBs. This pragmatic adaptive trial compares outcome in COVID-19 patients treated with lopinavir/ritonavir, hydroxychloroquine, losartan, and placebo.

NCT04328012 SARS-CoV-2 Infection Drug: lopinavir/ritonavir Drug: Hydroxychloroquine Sulfate Drug: Losartan Drug: Placebos

Primary Outcomes

Description: difference in NCOSS scores between the different treatment groups

Measure: National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)

Time: 60 days

Secondary Outcomes

Description: difference in the total inpatient LOS between the four treatment groups

Measure: Hospital length of stay (LOS)

Time: 60 days

Description: difference in the total ICU level care LOS between the four treatment groups

Measure: Intensive care unit level LOS

Time: 60 days

Description: difference in length of use of mechanical ventilation between the four treatment groups

Measure: Mechanical ventilation

Time: 60 days

Description: difference in all cause mortality between the four treatment groups

Measure: survival

Time: 60 days

No related HPO nodes (Using clinical trials)